The Post-Animal Era: Regulatory Shifts and Tech Innovation Disrupt Drug R&D
The long-standing paradigm of animal experimentation is facing an unprecedented decline as regulatory frameworks and advanced biotechnologies converge. Following the landmark FDA Modernization Act 2.0, the industry is pivoting toward 'New Approach Methodologies' that promise higher human predictive value and lower development costs.